Foghorn Therapeutics (FHTX) Cash from Operations (2019 - 2026)

Foghorn Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 25266000.0 for Q1 2026.

• In Q1 2026, Cash from Operations fell 5.42% year-over-year to 25266000.0; the TTM figure through Mar 2026 stood at 87397000.0 (up 8.03% YoY), while the FY2025 annual figure was 86099000.0, up 14.25% from the prior year.
• Cash from Operations for Q1 2026 stood at 25266000.0, down from 22271000.0 in the prior quarter.
• The five-year high for Cash from Operations was 271534000.0 in Q1 2022, with the low at 32175000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 25266000.0 (2026), against an average of 8015588.24.
• Peak annual rise in Cash from Operations reached 1273.09% in 2022, while the deepest fall reached 343.43% in 2022.
• Foghorn Therapeutics' Cash from Operations stood at 28924000.0 in 2022, then gained by 4.78% to 27541000.0 in 2023, then increased by 10.97% to 24519000.0 in 2024, then rose by 9.17% to 22271000.0 in 2025, then slipped by 13.45% to 25266000.0 in 2026.
• Business Quant data shows FHTX's Cash from Operations at 25266000.0 in Q1 2026, 22271000.0 in Q4 2025, and 18860000.0 in Q3 2025.